DJI136

Cell therapy

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Small Cell Lung Cancer
NCT07564401 · Novartis Pharmaceuticals
2026-06-16 – 2031-03-03 · Extensive-stage Small Cell Lung Cancer (ES-SCLC)
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Small Cell Lung Cancer: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
DJI136: this drugPhase 1/2Cell therapyDLL3not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
LurbinectedinApprovedSmall moleculeAlkylating DrugPartial signalNo reviewed efficacy summary in this indication
TarlatamabApprovedMultispecific antibodyDLL3 and CD3Partial signal
NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08).
NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025).
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-706Phase 3Antibody–drug conjugateSEZ6not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 3Small moleculeAurora B / FGFR / VEGFR (multi-kinase)Weak signal
NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022)
AtigotatugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
GocatamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ObrixtamigPhase 3Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AlisertibPhase 2Small moleculeAurora kinase A (AURKA)not yet gradedNo reviewed efficacy summary in this indication
SHR-4849
Phase 2(overall)
Antibody–drug conjugateDLL3
not yet graded(overall)
No reviewed efficacy summary in this indication
BMS-986525Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
225Ac-ETN029
—(overall)
Radioligand Therapy (actinium-225)DLL3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow DJI136 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2031 (1)
March 2031 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2031-03-03 · NCT07564401 · CT.gov ↗
What to watch

See the full readout calendar ↗